Sign In
Buy TRAW
$1.45
+0.0300 (+2.11%)
At Close: Jun 03, 2026
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
08:45am, Wednesday, 27'th May 2026
Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
07:00am, Friday, 15'th May 2026
Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027
Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak
10:41am, Friday, 08'th May 2026
Traws Pharma, Inc. (NASDAQ:TRAW) shares are up during Friday's session, trading higher by 25.86% as the company is advancing potential clinical candidates for the treatment of hantavirus infections.
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
07:30am, Friday, 08'th May 2026
NEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel the
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
10:56am, Monday, 20'th Apr 2026
Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement a
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
12:41am, Thursday, 16'th Apr 2026
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
04:01pm, Wednesday, 15'th Apr 2026
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,
Traws Pharma (NASDAQ:TRAW) Shares Up 8.8% – Should You Buy?
03:01am, Tuesday, 14'th Apr 2026
Traws Pharma, Inc. (NASDAQ: TRAW - Get Free Report) shot up 8.8% on Monday. The stock traded as high as $1.64 and last traded at $1.61. 21,635 shares were traded during trading, a decline of 60% from
Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; re
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpil
SAN DIEGO , Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services c
DOVER, Del. , Oct. 22, 2025 /PRNewswire/ -- Expert Systems Inc., a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates Phase 2 c
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
07:00am, Tuesday, 14'th Oct 2025
Non-inferiority trial versus PAXLOVID ® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatmen
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
04:00am, Monday, 06'th Oct 2025
NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
07:00am, Monday, 18'th Aug 2025
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID ®
